<HashMap><database>GEO</database><file_versions><headers><Content-Type>application/xml</Content-Type></headers><body><files><Other>ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE339nnn/GSE339459/</Other></files><type>primary</type></body><statusCode>OK</statusCode><statusCodeValue>200</statusCodeValue></file_versions><scores/><additional><omics_type>Transcriptomics</omics_type><species>Homo sapiens</species><gds_type>Expression profiling by high throughput sequencing</gds_type><full_dataset_link>https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE339459</full_dataset_link><repository>GEO</repository><entry_type>GSE</entry_type></additional><is_claimable>false</is_claimable><name>5β-Dihydrotestosterone and mutant androgen receptor vulnerability in prostate cancer</name><description>BACKGROUND Bipolar androgen therapy (BAT) exploits the paradoxical vulnerability of castration-resistant prostate cancer (CRPC) to supraphysiologic androgen, but current BAT uses testosterone (T), which broadly activates wild-type androgen receptor (AR) in normal androgen-responsive tissues and can cause systemic androgenic effects. 5β-Dihydrotestosterone (5β-DHT), a naturally occurring T metabolite, has been considered androgenically inactive because of weak wild-type AR activity. Here, we examined whether 5β-DHT and related 5β-reduced metabolites activate mutant AR signaling and reproduce BAT-like growth suppression. METHODS Six 5β-reduced T metabolites were evaluated in C4-2 and LNCaP prostate cancer cells under androgen-depleted and BAT-like conditions. AR dependence and mutant-specific activity were assessed using enzalutamide, AR-null PC-3 cells, and PC-3 cells expressing AR-W742C or AR-H875Y. Cell proliferation, AR-responsive reporter activity, RT-qPCR, RNA sequencing with gene set enrichment analysis, immunoblotting, and senescence-associated β-galactosidase staining were used to characterize ligand responses. RESULTS At nanomolar concentrations, 5β-DHT and 3β-etiocholanediol (3β-ecdiol) induced AR target genes and promoted AR-dependent C4-2 and LNCaP growth, although less potently than T. RNA sequencing showed that both metabolites activated the T-regulated AR transcriptional program with smaller differentially expressed gene footprints. At high concentrations, 5β-DHT, but not the weaker agonist 3β-ecdiol or progesterone-class steroids, suppressed C4-2 and LNCaP proliferation. High-dose 5β-DHT also activated AR and suppressed growth in PC-3 cells expressing AR-W742C or AR-H875Y, whereas AR-null PC-3 cells were unaffected. High-dose 5β-DHT enriched androgen-response and senescence programs, suppressed G2M, E2F, and MYC-associated pathways, increased p21, p27, and p57, reduced RB phosphorylation and SKP2, and induced senescence-associated β-galactosidase activity.</description><dates><publication>2026/08/08</publication></dates><accession>GSE339459</accession><cross_references><GSM>GSM9895982</GSM><GSM>GSM9895981</GSM><GSM>GSM9895980</GSM><GSM>GSM9895989</GSM><GSM>GSM9895988</GSM><GSM>GSM9895987</GSM><GSM>GSM9895986</GSM><GSM>GSM9895985</GSM><GSM>GSM9895984</GSM><GSM>GSM9895983</GSM><GSM>GSM9895993</GSM><GSM>GSM9896004</GSM><GSM>GSM9896003</GSM><GSM>GSM9895992</GSM><GSM>GSM9896002</GSM><GSM>GSM9895991</GSM><GSM>GSM9895990</GSM><GSM>GSM9896001</GSM><GSM>GSM9896000</GSM><GSM>GSM9895999</GSM><GSM>GSM9895998</GSM><GSM>GSM9896009</GSM><GSM>GSM9896008</GSM><GSM>GSM9895997</GSM><GSM>GSM9896007</GSM><GSM>GSM9895996</GSM><GSM>GSM9895995</GSM><GSM>GSM9896006</GSM><GSM>GSM9896005</GSM><GSM>GSM9895994</GSM><GPL>24676</GPL><GSE>339459</GSE><taxon>Homo sapiens</taxon></cross_references></HashMap>